Aptagen, LLC
XQ-P3 (ID# 8137)
DNA
PD-L1
Protein
15.36 nM (reported value)
D-PBS supplemented with 4.5 g/L of glucose, 5 mM of MgCl2, 0.1 mg/mL of yeast tRNA, and 1 mg/mL of BSA
22°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
5'-dApdCpdCpdGpdApdCpdCpdGpdTpdGpdCpdTpdGpdGpdApdCpdTpdCpdApdTpdCpdTpdCpdGpdCpdTpdTpdTpdTpdTpdTpdCpdApdCpdGpdGpdTpdCpdCpdApdCpdApdCpdTpdApdCpdTpdApdTpdGpdApdGpdCpdGpdApdGpdCpdCpdTpdGpdGpdCpdGp-3'
63
19261.5
573400
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Wu X, Li F, Li Y, Yu Y, Liang C, Zhang B, Zhao C, Lu A, Zhang G. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer. Med Sci Monit. 2020 Jun 23;26:e925583. doi: 10.12659/MSM.925583. PMID: 32574155; PMCID: PMC7331476.
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.